Comparison between efficacy of solifenacin and oxybutynin for the treatment of overactive bladder in women.

Abstract

Objective: To compare the efficacy of solifenacin and oxybutynin in the treatment of overactive bladder in female patients. Study Design: Quasi Experimental study. Setting: Department of Urology, Institute of Kidney Diseases, Peshawar. Period: July 2018 to May 2019. Material & Methods: After selection of 312 female patients with overactive bladder by simple random sampling, written informed consent was taken and pre-treatment overactive bladder symptoms (OABS) score was calculated. Patients were randomly distributed in two equal groups of 156 subjects, where Group A received Oxybutynin (3 mg, BD) and Group B received Solifenacin (5mg, OD) for a period 12 weeks. Patients were called for follow up visit to determine and compare the efficacy of study drugs. Those who showed improvement in at least 03 points in OABS score taken pre-treatment were considered as positive responders. Results: The mean age of patients was 38.8 ± 7.62 years with age range from 20 to 50 years. 110 (70.5%) subjects in oxybutynin treated group while 126 (80.8%) subjects in solifenacin treated group reported significant improvement in OAB symptoms. Conclusion: Solifenacin is relatively more effective than oxybutynin for treating female patients with overactive bladder.